Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer

@article{Hoy2013AbirateroneAA,
  title={Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer},
  author={Sheridan M. Hoy},
  journal={Drugs},
  year={2013},
  volume={73},
  pages={2077-2091}
}
Abiraterone acetate (Zytiga®) is an orally administered, selective inhibitor of the 17α-hydroxylase and C17,20-lyase enzymatic activities of cytochrome P450 (CYP) 17. CYP17 is required for androgen biosynthesis, with androgen receptor signalling crucial in the progression from primary to metastatic prostate cancer. Abiraterone acetate is approved in the European Union and the US, in combination with prednisone or prednisolone, for the treatment of men with metastatic castration-resistant… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
12 Citations
50 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Zytiga (abiraterone); 2012

  • European Medicines Agency. Assessment report
  • http://www.ema.europa.eu/docs/en_GB/document_…
  • 2013
Highly Influential
9 Excerpts

prescribing information; 2013

  • Janssen Biotech Inc. ZYTIGA tablets
  • http://www.accessdata.fda.gov/ drugsatfda_docs…
  • 2013
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…